EMA draft policy on access to clinical trial data

On Monday, 24 June 2013, the European Medicines Agency (EMA) published their draft policy on publication and access to clinical trial data.  The policy is open for public consultation until 30 September 2013. EMA were recently prevented from releasing clinical … Continue reading

New EMA guidance available for Parkinsons and Diabetes, CF endpoint workshop dates announced

In the past few weeks the European Medicines Agency has released updated guidance in a number of disease areas, including Parkinsons and diabetes, and they have published the dates of a workshop to discuss endpoints in development of new drugs … Continue reading

Pfizer’s tofacitinib appears to be as effective as Humira in Rheumatoid Arthritis (RA)

Pfizer provided details of tofacitinib data to be presented at the American College of Rheumatology (ACR) 2011 congress on 8 September.  The congress will be held on 5-9 November in Chicago. Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor under … Continue reading